




Documented
Success



Osseotite[®]

Implants



 **ZimVie**

The Osseotite Implant Overview

Proven Clinical Success

The Osseotite surface has more than 10 years of documentation from numerous global multi-center clinical studies¹⁻⁶ and meta-analyses.⁷⁻⁸ Clinical studies on the Osseotite surface continue to document the benefits of increased contact osteogenesis, especially in poor-quality bone.⁶

The Osseotite Implant features an acid-etched surface designed to facilitate osseointegration.





Image courtesy of Jun Y. Park, The Bone Interface Group.




Comprehensive Clinical Research

- One of the most well-researched dental implant surfaces on the market today
- Numerous studies report 98% cumulative success rates⁶

The Osseotite Surface

- Facilitates the Osseointegration process
- Demonstrates high contact of implant with new bone
- Human histology with demonstrated high bone-to-implant contact⁹



Osseotite surface at 20,000x magnification




Full Osseotite surface

- Five-year study¹⁰ showed no increased risk of Peri-implantitis vs. a ZimVie hybrid implant

The Osseotite Surface and the Healing Process

Blood Clotting and Implant Attachment

A blood clot attaches to an implant when its fibrin strands become intertwined in an implant's micro-surface features. The strength of the clot/implant attachment depends on how tightly the fibrin strands are entangled in the surface. Fibrin strands are typically sub-micron in diameter. Therefore, for the strongest bond, the implant surface features should create a maze of slightly larger spaces that can tightly capture the fibrin strands. Characterized by a 1 to 3 micron peak-to-peak surface created by a unique acid-etch process, the Osseotite surface features are precisely sized to entangle the fibrin strands of the blood clot.




The Osseotite surface features are precisely sized to entangle the fibrin strands

Platelet Aggregation

Platelet Activation Up-Regulates Healing Response

Osteogenic cell migration will occur through the blood clot and can be expected to be influenced by the release of cytokines and other growth factors from activated cellular components of the blood clot. In a study of red blood cell (RBC) and platelet interactions with implant surfaces, the amount of RBC agglomeration on the Osseotite surface was 54% greater than as seen on a smooth-machined surface.¹¹

In addition, platelet adhesion onto the Osseotite surface was enhanced by 110% in comparison to a smooth-machined surface.¹¹ RBC agglomeration is known to enhance blood clot permeability, which can lead to enhanced wound healing. Increased platelet activity can also lead to enhanced wound healing by the release of cytokines and growth factors.¹² Taken together, both platelet adhesion and RBC agglomeration can therefore result in increased bone formation on the Osseotite surface.




Enhanced microscopy image of the Osseotite surface showing platelet activation.

The Osseotite Surface and the Healing Process

Clot Attachment Increases Contact Osteogenesis


Contact Osteogenesis Facilitates Bone Healing

Bone heals around an implant through two distinct and overlapping phenomena: distance osteogenesis and contact osteogenesis. The rate and extent of healing around an implant is dependent on the degree of contact osteogenesis that occurs at the implant surface. The migration of osteogenic cells through the clot matrix causes contraction of the fibrin strands in the clot matrix, which can detach the strands from smooth-machined implant surfaces, disrupting or stopping contact osteogenesis and osteoconduction.¹³



Smooth - Machined Implant Healing Bone Existing Bone

Distance Osteogenesis –
A gradual process of bone healing inward from the edge of the osteotomy toward the implant. Bone does not grow directly on the implant surface.



Osseotite Implant Healing Bone Existing Bone

Contact Osteogenesis –
The direct migration of bone-building cells through the clot matrix to the implant surface. Bone is quickly formed directly on the implant surface.


The Osseotite Surface and Bone Contact

Human Histologic Data

In a study on the effect of implant surface features on bone healing, human histologic data confirmed the increase in osteoconduction and contact osteogenesis with the Osseotite surface as compared to a smooth-machined surface. Two 1-millimeter diameter screws, each having on one side an Osseotite surface and on the other side a smooth-machined surface, were placed in the posterior maxilla and removed after six months of healing.

The thirty-nine histologic sections prepared showed a mean percent bone/implant contact for the Osseotite surface of 72.96% as compared to 33.98% for the smooth-machined surface.⁹

Human Histology Matched Smooth-Machined and Osseotite Surface Pairs




Lazarra RJ[†], Testori T[†], Trisi P, Porter SS[†], Weinstein RL. A Human Histologic Analysis of Osseotite and Machined Surfaces Using Implants with Two Opposing Surfaces. *Int J Periodontics Restorative Dent*. 1999 Apr;19(2):117-129.

Full Osseotite Implants and Peri-implantitis

A Five-Year Study

A five-year prospective, multicenter, randomized-controlled study of the incidence of peri-implantitis for hybrid-DAE and fully-DAE implants.¹⁰

Considerations for potential benefits of extending the DAE surface to the seating surface led to this prospective randomized-controlled study designed to assess the risk and incidence of peri-implantitis for fully-DAE-surfaced implants (Full Osseotite/FOSS).  Full Osseotite surface


Study implants, fully-DAE-surfaced “test” implants, and hybrid-DAE “control” implants, were placed in a single-stage approach with the seating surface level with the crestal margin of the alveolar bone. The implants were allowed to heal for two months and were then provisionalized. Final restorations were placed at six months and patients were followed for five years at annual intervals. Follow-up evaluations included Sulcus Bleeding Index scores (SBI), probing for suppuration, assessments for mobility, and periapical radiographs to identify radiolucencies and crestal bone levels.

One hundred twelve patients were enrolled and 165 test and 139 control implants were placed supporting 127 prostheses. No substantial differences in mucosal health outcomes between test and control groups were observed throughout the five year follow-up. For both groups,

the bleeding-on-probing scores were no different. There was one case of peri-implantitis reported over the five years of observation and this was for a hybrid implant.

Radiographic analysis of crestal bone regression demonstrated that the mean change from baseline (provisionalization) is less for test implants in comparison to control implants ($P < .01$). The results of this five-year study showed no increased risk in adverse soft-tissue outcomes or peri-implantitis for fully-DAE-surfaced implants versus the control implants in this study.

Control
Implant:



Hybrid-DAE

Test
Implant:



Fully-DAE

Ordering Information

Certain® Internal Connection Implants Tapered

Osseotite Tapered Certain

Commercially Pure Titanium



Length	4/3.0 mmP	5/4.0 mmP	6/5.0 mmP
8.5 mm	XIITP4385	XIITP5485	XIITP6585
10 mm	XIITP4310	XIITP5410	XIITP6510
11.5 mm	XIITP4311	XIITP5411	XIITP6511
13 mm	XIITP4313	XIITP5413	XIITP6513
15 mm	XIITP4315	XIITP5415	XIITP6515

Full Osseotite Tapered Certain

Commercially Pure Titanium



Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	XIFNT3285	XIFNT485	XIFNT585	XIFNT685
10 mm	XIFNT3210	XIFNT410	XIFNT510	XIFNT610
11.5 mm	XIFNT3211	XIFNT411	XIFNT511	XIFNT611
13 mm	XIFNT3213	XIFNT413	XIFNT513	XIFNT613
15 mm	XIFNT3215	XIFNT415	XIFNT515	XIFNT615

Osseotite Tapered Certain

Commercially Pure Titanium




Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	INT3285	INT485	INT585	INT685
10 mm	INT3210	INT410	INT510	INT610
11.5 mm	INT3211	INT411	INT511	INT611
13 mm	INT3213	INT413	INT513	INT613
15 mm	INT3215	INT415	INT515	INT615

Certain Internal Connection Implants Parallel Walled

Osseotite 2 Parallel Walled Certain

Commercially Pure Titanium



Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	XIFOSM385	XIFOSS485	XIFOSS585	XIFOSS685
10 mm	XIFOSM310	XIFOSS410	XIFOSS510	XIFOSS610
11.5 mm	XIFOSM311	XIFOSS411	XIFOSS511	XIFOSS611
13 mm	XIFOSM313	XIFOSS413	XIFOSS513	XIFOSS613
15 mm	XIFOSM315	XIFOSS415	XIFOSS515	XIFOSS615

Osseotite Parallel Walled Certain

Titanium Alloy



Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	IOSS3285	IOSS585	IOSS585	IOSS685
10 mm	IOSS3210	IOSS410	IOSS510	IOSS610
11.5 mm	IOSS3211	IOSS411	IOSS511	IOSS611
13 mm	IOSS3213	IOSS413	IOSS513	IOSS613
13 mm	IOSS3215	IOSS415	IOSS515	IOSS615
15 mm	IOSS3218	IOSS4138	N/A	N/A
20 mm	N/A	IOSS420	N/A	N/A

Cover Screws

Included with Implant*

Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
Cover Screw Flat (included)				
	IMCSF34	ICSF41	ICSF50	ICSF60

*Non-Flared 4.1 mmP Cover Screw ICS400 is also available.

External Hex Connection Implants Tapered

Full Osseotite Tapered

Commercially Pure Titanium



Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	FNT3285	FNT485	FNT585	FNT685
10 mm	FNT3210	FNT410	FNT510	FNT610
11.5 mm	FNT3211	FNT411	FNT511	FNT611
13 mm	FNT3213	FNT413	FNT513	FNT613
15 mm	FNT3215	FNT415	FNT515	FNT615

Osseotite Tapered

Commercially Pure Titanium



Length	3.25 mmD	4.0 mmD	5.0 mmD	6.0 mmD
8.5 mm	NT3285	NT485	NT585	NT685
10 mm	NT3210	NT410	NT510	NT610
11.5 mm	NT3211	NT411	NT511	NT611
13 mm	NT3213	NT413	NT513	NT613
15 mm	NT3215	NT415	NT515	NT615

External Hex Connection Implants Parallel Walled

Osseotite 2 Parallel Walled

Commercially Pure Titanium



Length	3.25 mmD	3.75 mmD	4.0 mmD	5.0 mmD	6.0 mmD
6.5 mm	XFOSM365	XFOS365	XFOS465	XFOS565	XFOS665
8.5 mm	XFOSM385	XFOS385	XFOS485	XFOS585	XFOS685
10 mm	XFOSM310	XFOS310	XFOS410	XFOS510	XFOS610
11.5 mm	XFOSM311	XFOS311	XFOS411	XFOS511	XFOS611
13 mm	XFOSM313	XFOS313	XFOS413	XFOS513	XFOS613
15 mm	XFOSM315	XFOS315	XFOS415	XFOS515	XFOS615

Full Osseotite Parallel Walled

Commercially Pure Titanium



Length	3.25 mmD	3.75 mmD	4.0 mmD	5.0 mmD	6.0 mmD
7.0 mm	FOSM307	FOS307	FOS407	FOS507	FOS607
8.5 mm	FOSM385	FOS385	FOS485	FOS585	FOS685
10 mm	FOSM310	FOS310	FOS410	FOS510	FOS610
11.5 mm	FOSM311	FOS311	FOS411	FOS511	FOS611
13 mm	FOSM313	FOS313	FOS413	FOS513	FOS613
15 mm	FOSM315	FOS315	FOS415	FOS515	FOS615

Osseotite Parallel Walled

Commercially Pure Titanium



Length	3.25 mmD	3.75 mmD	4.0 mmD	5.0 mmD	6.0 mmD
7.0 mm	—	—	—	OSS507	OSS607
8.5 mm	OSM385	OSS385	OSS485	OSS585	OSS685
10 mm	OSM310	OSS310	OSS410	OSS510	OSS610
11.5 mm	OSM311	OSS311	OSS411	OSS511	OSS611
13 mm	OSM313	OSS313	OSS413	OSS513	OSS613
15 mm	OSM315	OSS315	OSS415	OSS515	OSS615
18 mm	OSM318	OSS318	OSS418	OSS518	OSS618
20 mm	—	OSS320	OSS420	—	—

References:

1. Sullivan DY, Sherwood RL, Porter SS. Long-Term Performance of Osseotite Implants: A Six-Year Clinical Follow-up. *Compendium Contin Edu Dent*. 2001 Apr;22(4):326-334.
 2. Davarpanah M, Martinez H, Etienne D, Zabalegui I, Mattout P, Chiche F, Michel J. A prospective multi-center evaluation of 1,538 3i implants: 1 to 5-year data. *Int J Oral Maxillofac Implants*. 2002 Nov-Dec;17(6):820-828.
 3. Feldman S, Boitel N, Weng D, Kohles SS, Stach RM[†]. Five-Year Survival Distributions of Short-Length (10mm or less) Machined-Surfaced and Osseotite Implants. *Clin Implant Dent Relat Res*. 2004;6(1):16-23.
 4. Sullivan D, Vincenzi G, Feldman S. Early Loading of Osseotite Implants 2 Months After Placement in the Maxilla and Mandible: A 5-year Report. *Int J Oral Maxillofac Implants* 2005 Nov-Dec;20(6):905-912.
 5. Stach RM[†], Kohles SS. A Meta-Analysis Examining the Clinical Survivability of Machined-Surfaced and Osseotite Implants in Poor-Quality Bone. *Implant Dent*. 2003;12(1):87-96.
 6. Testori T[†], Wiseman L, Woolfe S, Porter SS[†]. A Prospective Multicenter Clinical Study of the Osseotite Implant: Four-Year Interim Report. *Int J Oral Maxillofac Implants*. 2001 Mar-Apr;16(2):193-200.
 7. Gaucher H, Bentley K, Roy S, Head T, Blomfield J, Blondeau F, Nicholson L, Chehade A, Tardif N, Emery R[†]. A Multi-Centre Study of Osseotite Implants Supporting Mandibular Restorations: A 3-Year Report. *J Can Dent Assoc (Tor)*. 2001 Oct;67(9):528-533.
 8. Testori T[†], Fabbro MD, Feldman S, Vincenzi G, Sullivan D, Rossi R, Anitua E, Bianchi F, Francetti L, Weinstein RL. A Multicenter Prospective Evaluation of 2-months Loaded Osseotite Implants Placed in the Posterior Jaws: 3-year Follow-up Results. *Clin Oral Implants Res*. 2002 Apr;13(2):154-161.
 9. Lazarra RJ[†], Testori T[†], Trisi P, Porter SS[†], Weinstein RL. A Human Histologic Analysis of Osseotite and Machined Surfaces Using Implants with Two Opposing Surfaces. *Int J Periodontics Restorative Dent*. 1999 Apr;19(2):117-129.
 10. Zetterqvist L, Feldman S, Rotter B, Vincenzi G, Wennström JL, Chierico A[†], Stach RM[†], Kenealy JN[†]. A Prospective, Multicenter, Randomized-Controlled Five-Year Study of Hybrid and Fully-etched Implants for the Incidence of Peri-implantitis. *J Periodontol*. 2010 Apr;81(4):493-501.
 11. Park JY, Davies JE[†]. Red Blood Cell and Platelet Interactions with Titanium Implant Surfaces. *Clin Oral Implants Res*. 2000 Dec;11(6):530-539.
 12. Gemmell CH, Park JY. Initial Blood Interactions with Endosseous Implant Materials. *International bone engineering workshop; Bone engineering; 1999; Toronto, Canada. Chapter 9 in Bone Engineering (ed. Davies JE); Em Squared Inc. 2000 108-117pp.*
 13. Davies JE[†]. Mechanisms of Endosseous Integration. *Int J Prosthodont*. 1998 Sep-Oct;11(5):391-401.
- † Clinicians have or had a financial relationship with ZimVie Dental resulting from speaking engagements, consulting engagements and other retained services.

For more information, visit [ZimVie.com](https://www.zimvie.com)

ZimVie Dental
4555 Riverside Drive
Palm Beach Gardens, FL 33410
1-561-776-6700



Unless otherwise indicated, as referenced herein, all trademarks and intellectual property rights are the property of ZimVie Inc. or an affiliate; and all products are manufactured by one or more of the dental subsidiaries of ZimVie Inc. (Biomet 3i, LLC, Zimmer Dental, Inc., etc.) and marketed and distributed by ZimVie Dental and its authorized marketing partners. For additional product information, please refer to the individual product labeling or instructions for use. Product clearance and availability may be limited to certain countries/regions. This material is intended for clinicians only and does not comprise medical advice or recommendations. Distribution to any other recipient is prohibited. This material may not be copied or reprinted without the express written consent of ZimVie. ZV1507 REV A 09/23 ©2023 ZimVie. All rights reserved.

